COMMUNIQUÉS West-GlobeNewswire
-
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
18/03/2024 - 12:00 -
Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance
18/03/2024 - 12:05 -
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
18/03/2024 - 12:05 -
Major shareholder announcement – Invesco Ltd.
18/03/2024 - 12:25 -
Major shareholder announcement – AIM International Mutual Funds
18/03/2024 - 12:28 -
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
18/03/2024 - 12:28 -
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
18/03/2024 - 12:29 -
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
18/03/2024 - 12:30 -
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
18/03/2024 - 12:30 -
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
18/03/2024 - 12:30 -
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
18/03/2024 - 12:30 -
BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems
18/03/2024 - 12:30 -
Major shareholder announcement – BlackRock, Inc.
18/03/2024 - 12:32 -
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
18/03/2024 - 12:57 -
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
18/03/2024 - 13:00 -
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
18/03/2024 - 13:00 -
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
18/03/2024 - 13:00 -
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
18/03/2024 - 13:00 -
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
18/03/2024 - 13:00
Pages